focus -WSS

focus

author：focus 2025-09-27 22:47:42 - browse：4226

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Advisers to the Food and Drug Administration voted 11-0 on Monday to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly — ruling that the treatment’s ability to slow the cognitive decline in patients outweighed its safety risks.

The unanimous outcome of the daylong advisory panel was the best-case scenario for Lilly, making it likely that the FDA will approve the drug, called donanemab, for a broad population of people diagnosed with mild cognitive impairment due to Alzheimer’s. A decision is expected later this year.

“The benefits outweigh the risks, as long as the risks are being monitored,” said Kathleen Poston, a neurologist at Stanford University and a member of the advisory panel.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： The drug industry has found itself all alone in Washington

WSS

4 missing after record

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Air quality improving but still lags in Black, Hispanic communities

Inside the culture of fear in the White House science office of Eric Lander

Change Healthcare cyberattack prompts Medicare loan program

'The Earth is screaming at us': Gov. Inslee calls for climate action amid record heat

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Medical records are filled with copy

With psoriasis trial ahead, Alumis raises $259 million

BioMarin wins approval for gene therapy to treat hemophilia A

RSV shot was 90% effective at preventing hospitalizations in kids

Guidelines to prevent youth baseball injuries need more muscle

Where does female orgasm come from? Scientists think they know

Hollywood unions extend contract negotiations for actors

Just how do doctors, lawmakers, and the public define abortion?

Hepatitis C has a cure — but many Americans still lack access to it

In his State of the Union, Biden takes clear aim at 'Big Pharma'

hotspot

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

RSV shot was 90% effective at preventing hospitalizations in kids

Air quality improving but still lags in Black, Hispanic communities

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

FDA approves first blood sugar monitor without finger pricks

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

hotspot

hotspot

focus

Wikipedia